Key Takeaways
- Puma Biotechnology reported Q4 2025 adjusted earnings of 29 cents per share, surpassing estimates.
- Total revenues for Q4 reached $75.5 million, marking a 28% year-over-year increase.
- 2026 revenue guidance fell short of expectations, leading to a 14% drop in stock during after-hours trading.
Q4 Earnings Overview
Puma Biotechnology (PBYI) announced its fourth-quarter 2025 results, revealing adjusted earnings of 29 cents per share, exceeding the Zacks Consensus Estimate of 24 cents. This adjusted figure excludes stock-based compensation, while the reported earnings per share, including stock-based expenses, were 26 cents, down from 39 cents in the previous year’s quarter.
The company reported total revenues of $75.5 million for the fourth quarter, surpassing the consensus estimate of $68 million. This reflects a 28% year-over-year increase, driven by higher net product sales and significant growth in royalty revenues from international partners. Nerlynx (neratinib), PBYI’s sole marketed drug in the U.S., continues to lead product revenues, generating $59.9 million in Q4, which is nearly a 10% increase year over year.
Royalty revenues soared 232% to $15.6 million. However, total operating costs rose by 28% to $58.4 million, with selling, general, and administrative (SG&A) expenses increasing by 11% to $18.4 million. Research and development (R&D) costs also climbed by 11% to $16.8 million.
As of December 31, 2025, the company reported $97.5 million in cash and equivalents, a slight increase from $94.4 million at the end of September.
Full-Year Performance and Future Guidance
For the full year, Puma’s total revenues were $228.4 million, slightly down from $230.5 million in 2024. The adjusted net earnings for 2025 stood at 75 cents per share, a decline of 3.8% from the prior year.
Looking ahead, PBYI provided guidance for 2026, projecting net product revenues between $194 million and $198 million and royalty revenues of $20 million to $23 million, totaling revenues expected to range from $214 million to $221 million. This forecast falls short of the Zacks Consensus Estimate of $235.7 million, which negatively impacted investor confidence and resulted in a 14% stock decline during after-hours trading.
The company anticipates net income for 2026 to be between $10 million and $13 million, with SG&A expenses expected to rise by 3% to 5%. R&D expenses are projected to increase significantly by 30% to 35% to support ongoing clinical trials. For Q1 2026, Puma expects net product revenues of $36 million to $39 million and a net loss of approximately $8 million to $10 million.
Pipeline and Market Position
Puma Biotechnology continues to advance its pipeline, notably with alisertib, an aurora kinase A inhibitor licensed from Takeda in 2022. This drug is under investigation for various cancers, including hormone receptor-positive breast cancer and small-cell lung cancer. Updates on these studies are anticipated in the second quarter of 2026.
Currently, PBYI holds a Zacks Rank of #4 (Sell), with better-performing competitors such as Castle Biosciences (#1), ANI Pharmaceuticals (#2), and Assertio Holdings (#2) showing stronger market positioning.
The content above is a summary. For more details, see the source article.